Abstract:Background Galectin-9 is a member of the family of lectin proteins and crucially regulates human immune responses, particularly because of its ability to suppress the anticancer activities of T lymphocytes and natural killer cells. Recent evidence demonstrated that galectin-9 is highly expressed in a wide range of human malignancies including the most aggressive tumors, such as high-grade glioblastomas and pancreatic ductal adenocarcinomas, as well as common malignancies such as breast, lung and colorectal cancers. However, solid tumor cells at rest are known to secrete either very low amounts of galectin-9 or, in most of the cases, do not secrete it at all. Our aims were to elucidate whether T cells can induce galectin-9 secretion in human cancer cells derived from solid malignant tumors and whether this soluble form displays higher systemic immunosuppressive activity compared with the cell surface-based protein. Methods A wide range of human cancer cell lines derived from solid tumours, keratinocytes and primary embryonic cells were employed, together with helper and cytotoxic T cell lines and human as well as mouse primary T cells. Western blot analysis, ELISA, quantitative reverse transcriptase-PCR, on-cell Western and other measurement techniques were used to conduct the study. Results were validated using in vivo mouse model. Results We discovered that T lymphocytes induce galectin-9 secretion in various types of human cancer cells derived from solid malignant tumors. This was demonstrated to occur via two differential mechanisms: first by translocation of galectin-9 onto the cell surface followed by its proteolytic shedding and second due to autophagy followed by lysosomal secretion. For both mechanisms a protein carrier/trafficker was required, since galectin-9 lacks a secretion sequence. Secreted galectin-9 pre-opsonised T cells and, following interaction with other immune checkpoint proteins, their activity was completely attenuated. As an example, we studied the cooperation of galectin-9 and V-domain Ig-containing suppressor of T cell activation (VISTA) proteins in human cancer cells. Conclusion Our results underline a crucial role of galectin-9 in anticancer immune evasion. As such, galectin-9 and regulatory pathways controlling its production should be considered as key targets for immunotherapy in a large number of cancers.

Galectin-9 binding to HLA-DR in dendritic cells controls immune synapse formation and T cell proliferation

Galectin-9 regulates dendritic cell polarity and uropod contraction by modulating RhoA activity

Galectin-3 Modulates T Helper Responses by Regulating Dendritic Cell Cytokine Expression (103.11)

The N- and C-terminal carbohydrate recognition domains of galectin-9 contribute differently to its multiple functions in innate immunity and adaptive immunity.

Galectin-3 Modulates Th17 Responses by Regulating Dendritic Cell Cytokines.

Galectin-9 Expression Clinically Associated with Mature Dendritic Cells Infiltration and T Cell Immune Response in Colorectal Cancer

The interaction of galectin-8 C-terminal domain with cell surface glycoconjugates modulates membrane elasticity to stimulate antigen uptake and presentation to CD4 T cells

T lymphocytes induce human cancer cells derived from solid malignant tumors to secrete galectin-9 which facilitates immunosuppression in cooperation with other immune checkpoint proteins

Galectin-9 is a Novel Regulator of Epithelial Restitution.

Galectin-9 Enhances Cytokine Secretion, but Suppresses Survival and Degranulation, in Human Mast Cell Line

Galectin-1 Induces the Production of Immune-Suppressive Cytokines in Human and Mouse T Cells

Galectin-9 - ligand axis: an emerging therapeutic target for multiple myeloma

Galectin-9 protein is up-regulated in astrocytes by tumor necrosis factor and promotes encephalitogenic T-cell apoptosis

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy

CD9 Regulates Major Histocompatibility Complex Class II Trafficking in Monocyte-Derived Dendritic Cells

Galectin-9, a pro-survival factor inducing immunosuppression, leukemic cell transformation and expansion

Abstract 2882: Characteristic immunomodulatory role of myeloid galectin-9 in the brain tumor microenvironment

Galectin-9 Promotes a Suppressive Microenvironment in Human Cancer by Enhancing STING Degradation

Cross-Linking of Gm1 Ganglioside by Galectin-1 Mediates Regulatory T Cell Activity Involving Trpc5 Channel Activation: Possible Role in Suppressing Experimental Autoimmune Encephalomyelitis

Galectin-9 Mediates the Functions of Microglia in the Hypoxic Brain Tumor Microenvironment

Chemokines modulate glycan binding and the immunoregulatory activity of galectins